Our Business

Our goal is to create and develop innovative healthcare solutions all based on the unique properties of human fibrinogen.

Fibriant was founded in 2015 and is located in Leiden, The Netherlands. The Research and Development Facility is located in the Bioscience Park adjacent to the campus of the renowned University of Leiden.

Our core activity is the manufacturing and characterization of specific variants of fibrinogen.

Fibriant executes a hybrid business model:

  • we use the fibrinogen technology platform for internal product and lead development and
  • we support research and product development of others

Fibriant has an extensive network of academic and industrial collaborations that support our research and development activities. Our partnerships include major players in fibrinogen structure-function research and recombinant protein production and experts in the field of tissue repair and remodeling as well as host defense and inflammation.

Company Strategy

The goal of Fibriant™’s business strategy is to establish a profitable, sustainable R & D company that can substantially contribute to human healthcare at the short term and in the long run. To achieve this goal Fibriant will follow a step-by-step approach that will balance the generation of near-term revenues while preserving the potential for high returns over the longer term.

Fibriant™’s strategy to generate near-term revenues within the first three years is focussed on contract R & D services in the field of haemostasis and fibrinogen for other companies and supply of recombinant fibrinogen variants. Additional revenues will be generated by out-licensing IP, technology and know-how, outside the scope of Fibriant™’s own product development programs, to other parties.

Fibriant™’s long-term strategy to maximize revenues after three years involves contract manufacturing of clinical and commercial grade recombinant fibrinogen and out-licensing of product development opportunity after pre-clinical or early clinical Proof-of-Concept. The company may also spin-out specific assets into a “special purpose vehicle” for further development and funding.

Our Team

Between them, the founder and co-founders of Fibriant have extensive expertise in all areas relevant to our business: from applied and fundamental fibrinogen research to biopharmaceutical product development.

The founder, Jaap Koopman, combines a strong scientific background in fibrinogen research with experience in biopharmaceutical product development and entrepreneurship in biotechnology. Co-founders, Miranda Weggeman and Jos Grimbergen, have been working on fibrinogen related R & D projects for over 6 years at ProFibrix where they made a valuable contribution to obtaining market approval (H1 2015) for the fibrinogen based product Raplixa.


Jaap Koopman


Jaap Koopman has over 30 years experience in bio-medical research focusing on various aspects of fibrinogen and fibrin formation. He received his PhD in 1992 at the University of Leiden, The Netherlands and has published over 30 peer reviewed scientific papers and has received several national and international scientific awards. In 2004 he founded ProFibrix and as CEO led the company to multiple venture finance rounds. In 2011 Jaap became the CSO of ProFibrix and after the successful acquisition of ProFibrix by The Medicines Company in August 2013 became VP Research up to Dec 2014. As of July 2015 he is founder and CEO of Fibriant.

Jos Grimbergen


Jos Grimbergen has been active in the field of cardiovascular research for more than 20 years. In 2007 he was the first employee to join ProFibrix BV as Director Research, and has been responsible for the early development and analytical support for Raplixa™ and the Fibrospray device. Besides the Raplixa™ program he was responsible for development of the up-stream process for recombinant fibrinogen. From August 2013 to June 2015 Jos was Director Research at The Medicines Company. As of July 2015 he is co-founder and COO of Fibriant.

Miranda Weggeman


Miranda Weggeman has been active in the biopharmaceutical industry for over 20 years. She worked at Pharming, Crucell and SynCo Bio Partners before joining ProFibrix in 2009. Miranda has been responsible for the development of the down-stream process for recombinant Fibrinogen and has been involved in optimizing the Phase 3 RaplixaTM manufacturing process and analytical development. From August 2013 to June 2015 Miranda was Director down-stream process development at The Medicines Company. As of July 2015 she is co-founder and CTO of Fibriant.


Linda Huisman, Maureen de Jong and Rene van Ommen have worked together on recombinant fibrinogen projects for over 5 years at ProFibrix and are experts in the field of clone generation and selection, protein purification and structural and functional characterization of fibrinogen.